|
|
|
|
| LEADER |
00000cam a22000007a 4500 |
| 001 |
SCIDIR_on1392340432 |
| 003 |
OCoLC |
| 005 |
20231120010750.0 |
| 006 |
m o d |
| 007 |
cr |n||||||||| |
| 008 |
230806s2023 xx o 000 0 eng d |
| 040 |
|
|
|a YDX
|b eng
|c YDX
|d SFB
|d OPELS
|d UKMGB
|
| 015 |
|
|
|a GBC3B1204
|2 bnb
|
| 016 |
7 |
|
|a 021089841
|2 Uk
|
| 020 |
|
|
|a 9780443192500
|q (electronic bk.)
|
| 020 |
|
|
|a 0443192502
|q (electronic bk.)
|
| 020 |
|
|
|z 9780443192494
|
| 035 |
|
|
|a (OCoLC)1392340432
|
| 050 |
|
4 |
|a RC271.I45
|
| 082 |
0 |
4 |
|a 616.994061
|
| 245 |
0 |
0 |
|a Viral vectors in cancer immunotherapy /
|c edited by Fernando Aranda, Pedro Berraondo, Lorenzo Galluzzi.
|
| 260 |
|
|
|a [S.l.] :
|b Academic Press,
|c 2023.
|
| 300 |
|
|
|a 1 online resource.
|
| 336 |
|
|
|a text
|2 rdacontent
|
| 337 |
|
|
|a computer
|2 rdamedia
|
| 338 |
|
|
|a online resource
|2 rdacarrier
|
| 490 |
0 |
|
|a International review of cell and molecular biology ;
|v volume 379
|
| 505 |
0 |
|
|a Front Cover -- Series page -- International Review of CELL AND MOLECULARBIOLOGY -- Copyright -- Contents -- Contributors -- Chapter One: Viral vectors engineered for gene therapy -- 1 Introduction -- 2 Viral vectors for gene therapy -- 3 Gene therapy applications using viral vectors -- 3.1 Cancer therapy -- 3.2 Cardiovascular and metabolic diseases -- 3.3 Hematological diseases -- 3.4 Neurological disorders -- 3.5 Muscular diseases -- 3.6 Immunodeficiency -- 3.7 Infectious diseases -- 3.8 Other diseases -- 4 Challenges for viral vector-based gene therapy -- 5 Conclusions and perspectives -- References -- Chapter Two: Checkpoint blockade meets gene therapy: Opportunities to improve response and reduce toxicityCheckpoint blockade meets gene therapy -- 1 Introduction -- 2 Immune checkpoints in cancer immunotherapy -- 3 Types of antibodies used in cancer immunotherapy -- 4 Local delivery of immune checkpoint inhibitors: Prospects for gene therapy -- 5 Oncolytic viruses expressing ICIs -- 6 Non-oncolytic vectors expressing ICIs -- 7 Self-amplifying RNA vectors expressing ICIs -- 8 Combination of vectors expressing ICIs with other therapies -- 8.1 Combination with systemically administered ICIs -- 8.2 Combination with CAR-T cells -- 8.3 Combination with depletion of immunosuppressive cells -- 8.4 Combination with radiation and chemotherapy -- 9 Conclusions -- Competing interests -- Acknowledgements -- References -- Chapter Three: Armored modified vaccinia Ankara in cancer immunotherapy -- 1 Introduction -- 2 MVA as potent immune activator -- 2.1 Cell and tissue tropism -- 2.2 Innate immune activation -- 2.3 Induction of cell death -- 2.4 Generation of adaptive immune responses -- 3 Tumor antigens encoded in MVA vaccines -- 3.1 HER2 -- 3.2 P53 -- 3.3 Brachyury -- 3.4 5T4 -- 3.5 MUC1 and CEA -- 3.6 Self- and virus-derived neoantigens.
|
| 505 |
8 |
|
|a 3.7 Novel TAA candidates -- 4 MVA cancer vaccines expressing immune modulatory molecules -- 4.1 MVA-TRICOM -- 4.2 MVA-CD40L -- 4.3 MVA-IL-2 -- 4.4 Novel candidates -- 5 Maximizing MVA cancer vaccine effectiveness: A comprehensive exploration of delivery routes -- 5.1 Alternative immunization routes to enhance MVA-based immune modulation -- 5.2 The impact of immunization routes on the efficacy of armed MVA -- 6 Conclusions and outlook -- References -- Chapter Four: Alphaviruses in cancer immunotherapyAlphaviruses in cancer immunotherapy -- 1 Introduction -- 2 Alphavirus vectors -- 2.1 Recombinant particles -- 2.2 Oncolytic alphaviruses -- 2.3 RNA replicon vectors -- 2.4 DNA replicon vectors -- 3 Alphavirus-based cancer therapy -- 3.1 Antitumor, cytotoxic, and suicide genes -- 3.2 Cancer vaccines -- 3.3 Cancer immunotherapy -- 3.4 Oncolytic alphaviruses -- 4 Alphaviruses in comparison to other approaches -- 4.1 Conventional non-viral vectors versus self-replicating alphavirus DNA vectors -- 4.2 Other viral vectors versus recombinant self-replicating alphavirus particles -- 4.3 Synthetic mRNA molecules versus self-replicating RNA replicons -- 5 Conclusions -- References -- Chapter Five: Oncolytic viruses as treatment for adult and pediatric high-grade gliomas: On the way to clinical successOncolytic viruses as treatment for adult and pediatric high-grade gliomas -- 1 High-grade gliomas -- 2 Oncolytic viruses -- 3 Adult high-grade glioma clinical trials -- 3.1 Herpes simplex virus type-1(HSV-1) -- 3.2 Adenoviruses -- 3.3 Other oncolytic viruses -- 4 Pediatric high-grade glioma clinical trials -- 5 Discussion and future perspectives -- References -- Chapter Six: Oncolytic viruses in hematological malignancies: hijacking disease biology and fostering new promises for immune and cell-based therapiesOncolytic viruses in hematological malignancies.
|
| 505 |
8 |
|
|a 1 Introduction -- 2 Families of oncolytic viruses and mechanisms of action -- 2.1 General biology of viruses -- 2.2 Family of viruses with potential application in oncolytic therapy -- 2.3 Virotherapy principles: cell signaling and immunopathogenesis in viral infection response -- 2.4 Viral oncolytic strategies, cell signaling disruption, and immune reprogramming -- 3 Virotherapy approaches in hematological malignancies -- 3.1 Precursor myeloid malignancies -- 3.2 Precursor lymphoid malignancies -- 3.3 Myeloproliferative neoplasms -- 3.4 Mature lymphoid malignancies -- 3.4.1 B cell-derived malignancies -- 3.4.2 T cell-derived malignancies -- 3.5 Multiple myeloma -- 3.6 Combinatorial strategies to enhance immunogenic cell death -- 4 Conclusion -- References -- Chapter Seven: Oncolytic virotherapy in lung cancerOncolytic virotherapy in lung cancer -- 1 The lung cancer scenario -- 2 Immune therapy in lung cancer -- 3 Oncolytic virotherapy -- 3.1 DNA viruses -- 3.1.1 Adenoviruses -- 3.1.2 Poxviruses -- 3.1.3 Herpesvirus -- 3.1.4 Parvovirus -- 4 RNA viruses -- 4.1 Paramyxovirus -- 4.2 Rhabdovirus -- 4.3 Orthomyxovirus -- 4.4 Picornavirus -- 4.5 Reovirus -- 5 Discussion -- Acknowledgments -- References -- Chapter Eight: Rational selection of an ideal oncolytic virus to address current limitations in clinical translationRational selection of an ideal oncolytic virus to address current limitations in clinical translation -- 1 Introduction -- 2 Oncolytic virus landscape -- 2.1 Adenovirus -- 2.2 Herpes simplex virus -- 2.3 Vaccinia virus -- 2.4 Reovirus -- 2.5 Measles virus -- 3 Ideal properties of an oncolytic virus therapy -- 4 Vesicular stomatitis virus -- 4.1 Selectivity -- 4.2 Therapeutic transgenes -- 4.3 Genome stability -- 5 Conclusion -- Competing interests -- Acknowledgments -- References -- Backcover.
|
| 588 |
0 |
|
|a Print version record.
|
| 650 |
|
0 |
|a Cancer
|x Immunotherapy.
|
| 650 |
|
0 |
|a Cancer
|x Gene therapy.
|
| 650 |
|
0 |
|a Genetic vectors
|x Therapeutic use.
|
| 650 |
|
2 |
|a Immunotherapy.
|
| 650 |
|
2 |
|a Cancer Vaccines.
|
| 650 |
|
2 |
|a Oncolytic Virotherapy.
|
| 650 |
|
2 |
|a Oncolytic Viruses.
|
| 650 |
|
2 |
|a Genetic Therapy.
|
| 776 |
0 |
8 |
|i ebook version :
|z 9780443192500
|
| 776 |
0 |
8 |
|c Original
|z 0443192499
|z 9780443192494
|w (OCoLC)1360262480
|
| 776 |
0 |
8 |
|i Print version:
|t VIRAL VECTORS IN CANCER IMMUNOTHERAPY.
|d [S.l.] : ELSEVIER ACADEMIC PRESS, 2023
|z 0443192499
|w (OCoLC)1360262480
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/bookseries/19376448/379
|z Texto completo
|
